A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardACTRN 12618001112257 Brief Summary This is a Phase I, open-label, single arm,…
Read more arrow_forwardACTRN 12618001070224 Brief Summary This is a Phase I, open-label, single arm,…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardNCT 05914116 Brief Summary This is a dose-escalation and dose-expansion Phase 1/2a…
Read more arrow_forwardACTRN 12622000993796 Brief Summary AXA-042 functions through a multi-cellular mechanism to re-engage…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardACTRN 12620000592943 Brief Summary This purpose of this study is to determine…
Read more arrow_forwardACTRN 12623000307606 Brief Summary This study is investigating a new cancer treatment…
Read more arrow_forward